SLC5A2 and diabetes mellitus: Sodium-glucose cotransporter-2 inhibitors (SGLT-2) inhibitors were initially developed as medications to treat diabetes mellitus as they block proximal renal tubular glucose reabsorption, leading to increased glucosuria and lowering of hemoglobin A1c.